Cargando…

Hypoxia-inducible factor-1α gene polymorphisms and cancer risk: a meta-analysis

BACKGROUND: The results from the published studies on the association between hypoxia-inducible factor -1α (HIF-1α) polymorphisms and cancer risk are conflicting. In this meta-analysis, we aimed to investigate the association between HIF-1α 1772 C/T and 1790 G/A polymorphisms and cancer. METHODS: Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Tongfeng, Lv, Jing, Zhao, Jiangpei, Nzekebaloudou, Marius
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804603/
https://www.ncbi.nlm.nih.gov/pubmed/20035632
http://dx.doi.org/10.1186/1756-9966-28-159
_version_ 1782176163376922624
author Zhao, Tongfeng
Lv, Jing
Zhao, Jiangpei
Nzekebaloudou, Marius
author_facet Zhao, Tongfeng
Lv, Jing
Zhao, Jiangpei
Nzekebaloudou, Marius
author_sort Zhao, Tongfeng
collection PubMed
description BACKGROUND: The results from the published studies on the association between hypoxia-inducible factor -1α (HIF-1α) polymorphisms and cancer risk are conflicting. In this meta-analysis, we aimed to investigate the association between HIF-1α 1772 C/T and 1790 G/A polymorphisms and cancer. METHODS: The meta-analysis for 1772 C/T polymorphism included 4131 cancer cases and 5387 controls, and for 1790 G/A polymorphism included 2058 cancer cases and 3026 controls. Allelic and genotypic comparisons between cases and controls were evaluated. Subgroup analyses by cancer types, ethnicity, and gender were also performed. We included prostate cancer in male subgroup, and female specific cancers in female subgroup. RESULTS: For the 1772 C/T polymorphism, the analysis showed that the T allele and genotype TT were significantly associated with higher cancer risk: odds ratio (OR) = 1.29 [95% confidence interval (CI, 1.01, 1.65)], P = 0.04, P(heterogeneity )< 0.00001, and OR = 2.18 [95% CI (1.32, 3.62)], P = 0.003, P(heterogeneity )= 0.02, respectively. The effect of the genotype TT on cancer especially exists in Caucasians and female subjects: OR = 2.40 [95% CI (1.26, 4.59)], P = 0.008, P(heterogeneity )= 0.02, and OR = 3.60 [95% CI (1.17, 11.11)], P = 0.03, P(heterogeneity )= 0.02, respectively. For the 1790 G/A polymorphism, the pooled ORs for allelic frequency comparison and dominant model comparison suggested a significant association of 1790 G/A polymorphism with a decreased breast cancer risk: OR = 0.28 [95% CI (0.08, 0.90)], P = 0.03, P(heterogeneity )= 0.45, and OR = 0.29 [95% CI (0.09, 0.97)], P = 0.04, P(heterogeneity )= 0.41, respectively. The frequency of the HIF-1α 1790 A allele was very low and only two studies were included in the breast cancer subgroup. CONCLUSIONS: Our meta-analysis suggests that the HIF-1α 1772 C/T polymorphism is significantly associated with higher cancer risk, and 1790 G/A polymorphism is significantly associated with decreased breast cancer risk. The effect of the 1772 C/T polymorphism on cancer especially exists in Caucasians and female subjects. Only female specific cancers were included in female subgroup, which indicates that the 1772 C/T polymorphism is significantly associated with an increased risk for female specific cancers. The association between the 1790 G/A polymorphism and lower breast cancer risk could be due to chance.
format Text
id pubmed-2804603
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28046032010-01-12 Hypoxia-inducible factor-1α gene polymorphisms and cancer risk: a meta-analysis Zhao, Tongfeng Lv, Jing Zhao, Jiangpei Nzekebaloudou, Marius J Exp Clin Cancer Res Research BACKGROUND: The results from the published studies on the association between hypoxia-inducible factor -1α (HIF-1α) polymorphisms and cancer risk are conflicting. In this meta-analysis, we aimed to investigate the association between HIF-1α 1772 C/T and 1790 G/A polymorphisms and cancer. METHODS: The meta-analysis for 1772 C/T polymorphism included 4131 cancer cases and 5387 controls, and for 1790 G/A polymorphism included 2058 cancer cases and 3026 controls. Allelic and genotypic comparisons between cases and controls were evaluated. Subgroup analyses by cancer types, ethnicity, and gender were also performed. We included prostate cancer in male subgroup, and female specific cancers in female subgroup. RESULTS: For the 1772 C/T polymorphism, the analysis showed that the T allele and genotype TT were significantly associated with higher cancer risk: odds ratio (OR) = 1.29 [95% confidence interval (CI, 1.01, 1.65)], P = 0.04, P(heterogeneity )< 0.00001, and OR = 2.18 [95% CI (1.32, 3.62)], P = 0.003, P(heterogeneity )= 0.02, respectively. The effect of the genotype TT on cancer especially exists in Caucasians and female subjects: OR = 2.40 [95% CI (1.26, 4.59)], P = 0.008, P(heterogeneity )= 0.02, and OR = 3.60 [95% CI (1.17, 11.11)], P = 0.03, P(heterogeneity )= 0.02, respectively. For the 1790 G/A polymorphism, the pooled ORs for allelic frequency comparison and dominant model comparison suggested a significant association of 1790 G/A polymorphism with a decreased breast cancer risk: OR = 0.28 [95% CI (0.08, 0.90)], P = 0.03, P(heterogeneity )= 0.45, and OR = 0.29 [95% CI (0.09, 0.97)], P = 0.04, P(heterogeneity )= 0.41, respectively. The frequency of the HIF-1α 1790 A allele was very low and only two studies were included in the breast cancer subgroup. CONCLUSIONS: Our meta-analysis suggests that the HIF-1α 1772 C/T polymorphism is significantly associated with higher cancer risk, and 1790 G/A polymorphism is significantly associated with decreased breast cancer risk. The effect of the 1772 C/T polymorphism on cancer especially exists in Caucasians and female subjects. Only female specific cancers were included in female subgroup, which indicates that the 1772 C/T polymorphism is significantly associated with an increased risk for female specific cancers. The association between the 1790 G/A polymorphism and lower breast cancer risk could be due to chance. BioMed Central 2009-12-27 /pmc/articles/PMC2804603/ /pubmed/20035632 http://dx.doi.org/10.1186/1756-9966-28-159 Text en Copyright ©2009 Zhao et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Zhao, Tongfeng
Lv, Jing
Zhao, Jiangpei
Nzekebaloudou, Marius
Hypoxia-inducible factor-1α gene polymorphisms and cancer risk: a meta-analysis
title Hypoxia-inducible factor-1α gene polymorphisms and cancer risk: a meta-analysis
title_full Hypoxia-inducible factor-1α gene polymorphisms and cancer risk: a meta-analysis
title_fullStr Hypoxia-inducible factor-1α gene polymorphisms and cancer risk: a meta-analysis
title_full_unstemmed Hypoxia-inducible factor-1α gene polymorphisms and cancer risk: a meta-analysis
title_short Hypoxia-inducible factor-1α gene polymorphisms and cancer risk: a meta-analysis
title_sort hypoxia-inducible factor-1α gene polymorphisms and cancer risk: a meta-analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804603/
https://www.ncbi.nlm.nih.gov/pubmed/20035632
http://dx.doi.org/10.1186/1756-9966-28-159
work_keys_str_mv AT zhaotongfeng hypoxiainduciblefactor1agenepolymorphismsandcancerriskametaanalysis
AT lvjing hypoxiainduciblefactor1agenepolymorphismsandcancerriskametaanalysis
AT zhaojiangpei hypoxiainduciblefactor1agenepolymorphismsandcancerriskametaanalysis
AT nzekebaloudoumarius hypoxiainduciblefactor1agenepolymorphismsandcancerriskametaanalysis